View in EDS

Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes.

Saved in:
Bibliographic Details
Title: Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes.
Authors: Merz AMA; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany., Sébert M; Service Hématologie Séniors, Hôpital Saint-Louis (AP-HP), Paris Cité University and INSERM U944, Paris, France., Sonntag J; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany., Kubasch AS; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany., Platzbecker U; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany. Electronic address: uwe.platzbecker@medizin.uni-leipzig.de., Adès L; Service Hématologie Séniors, Hôpital Saint-Louis (AP-HP), Paris Cité University and INSERM U944, Paris, France. Electronic address: lionel.ades@aphp.fr.
Source: Cancer treatment reviews [Cancer Treat Rev] 2024 Feb; Vol. 123, pp. 102673. Date of Electronic Publication: 2023 Dec 19.
Publication Type: Journal Article; Review
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7502030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1967 (Electronic) Linking ISSN: 03057372 NLM ISO Abbreviation: Cancer Treat Rev Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38176221
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Merz+AMA%22">Merz AMA</searchLink>; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany.<br /><searchLink fieldCode="AU" term="%22Sébert+M%22">Sébert M</searchLink>; Service Hématologie Séniors, Hôpital Saint-Louis (AP-HP), Paris Cité University and INSERM U944, Paris, France.<br /><searchLink fieldCode="AU" term="%22Sonntag+J%22">Sonntag J</searchLink>; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany.<br /><searchLink fieldCode="AU" term="%22Kubasch+AS%22">Kubasch AS</searchLink>; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany.<br /><searchLink fieldCode="AU" term="%22Platzbecker+U%22">Platzbecker U</searchLink>; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University Hospital of Leipzig, Leipzig, Germany. Electronic address: uwe.platzbecker@medizin.uni-leipzig.de.<br /><searchLink fieldCode="AU" term="%22Adès+L%22">Adès L</searchLink>; Service Hématologie Séniors, Hôpital Saint-Louis (AP-HP), Paris Cité University and INSERM U944, Paris, France. Electronic address: lionel.ades@aphp.fr.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227502030%22">Cancer treatment reviews</searchLink> [Cancer Treat Rev] 2024 Feb; Vol. 123, pp. 102673. <i>Date of Electronic Publication: </i>2023 Dec 19.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>7502030 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-1967 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203057372%22">03057372 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Treat Rev <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38176221
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ctrv.2023.102673
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 102673
    Titles:
      – TitleFull: Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Merz AMA
      – PersonEntity:
          Name:
            NameFull: Sébert M
      – PersonEntity:
          Name:
            NameFull: Sonntag J
      – PersonEntity:
          Name:
            NameFull: Kubasch AS
      – PersonEntity:
          Name:
            NameFull: Platzbecker U
      – PersonEntity:
          Name:
            NameFull: Adès L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2024 Feb
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1532-1967
          Numbering:
            – Type: volume
              Value: 123
          Titles:
            – TitleFull: Cancer treatment reviews
              Type: main
ResultId 1